MedTrace Logo

PHOX2B PC-CAR T Cells for Relapsed Neuroblastoma

NCT07007117 · Status: RECRUITING · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 38

Last updated 2025-12-26

No results posted yet for this study

Summary

This is a first in human dose escalation trial to determine the safety of administering PHOX2B PC-CAR T cells in patients with advanced, high-risk neuroblastoma.

Conditions

  • Refractory Neuroblastoma
  • Relapsed Neuroblastoma
  • High-Risk Neuroblastoma

Interventions

BIOLOGICAL

PHOX2B PC-CAR T Cells

The PHOX2B PC-CAR T cell investigational product is comprised of autologous human T cells that have been genetically modified to express a a PHOX2B-targeting chimeric antigen receptor (CAR) transgene.

Sponsors & Collaborators

  • Children's Hospital of Philadelphia

    collaborator OTHER

  • Alliance for Cancer Gene Therapy

    collaborator OTHER

  • Children's Cancer Research Fund

    collaborator OTHER

  • Stephan Grupp MD PhD

    lead OTHER

Principal Investigators

  • Jacquelyn Crane, MD · Children's Hospital of Philadelphia

  • Stephan A. Grupp, MD, PhD · Children's Hospital of Philadelphia

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SEQUENTIAL

Eligibility

Min Age
1 Year
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-06-20
Primary Completion
2032-06-30
Completion
2035-06-30
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07007117 on ClinicalTrials.gov